Ipsen【IPN】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

111.10

買値

111.00

売値

111.90

出来高

65,052

109.40 日の範囲 111.80

99.70 52 週間の範囲 126.70

時価総額

9.113B

前日終値

108.90

始値

109.40

時刻

111.1

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

61,860

発行済株式数

82,029,421

配当利回り

1.08%

PER

14.22

1 株当たり利益 (EPS)

7.86

歳入

3.37B

純利益

644.4M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.ipsen.com

本社

Boulogne-billancourt, Hauts-de-seine, Fra

設立

Ipsen SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker IPN. The last closing price for Ipsen was 108.90 €. Over the last year, Ipsen shares have traded in a share price range of 99.70 € to 126.70 €.

Ipsen currently has 82,029,421 shares in issue. The market capitalisation of Ipsen is 8.93 € billion. Ipsen has a price to earnings ratio (PE ratio) of 14.22.

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Ipsen secures exclusive global rights to develop, manufacture and...

Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie

Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie Ipsen obtient les droits mondiaux...

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across...

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG Ipsen met en avant...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today...

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus Ipsen presents 3 late-breaking presentations and 8 abstracts...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September...

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.3	0.270758122744	110.8	111.8	107.5	48752	109.27949762	DE
4	-1.6	-1.41969831411	112.7	113.7	105.5	62861	109.59806843	DE
12	1.5	1.36861313869	109.6	117.5	104.6	61860	111.0725669	DE
26	-9.2	-7.64754779717	120.3	126.7	100.3	66961	111.21866288	DE
52	10.3	10.2182539683	100.8	126.7	99.7	71018	109.78756299	DE
156	23.92	27.4374856618	87.18	130.7	77	80395	104.35460088	DE
260	10.6	10.5472636816	100.5	130.7	34.2	102800	88.64948142	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ALCYBCybergun	0.0002 € (100.00%)	10.06M
ALVETEGEIRO Pharma	0.124 € (58.97%)	481.8k
ALDVAlliance Developpement Capital Siic	0.074 € (32.14%)	6k
MLSRPSpeed Rabbit Pizza	8.20 € (30.16%)	19
MLSEQSequa Petroleum NV	0.011 € (29.41%)	12k
MLCOTCoretech 5	0.01 € (-41.18%)	200
ATOAtos SE	0.495 € (-32.65%)	17.92M
AFMEAffluent Medical	1.20 € (-21.05%)	21.92k
ALBIOBiosynex	2.095 € (-18.32%)	26.9k
TRACTTeract SA	1.03 € (-15.23%)	76.91k
BCPBanco Comercial Portugues SA	0.4457 € (2.20%)	44.64M
ALNEVNeovacs	0.0003 € (0.00%)	33.59M
ATOAtos SE	0.495 € (-32.65%)	17.92M
ALCYBCybergun	0.0002 € (100.00%)	10.06M
ORAOrange.	9.706 € (-2.99%)	9.65M